Transcode Therapeutics Inc (RNAZ) - Total Liabilities
Based on the latest financial reports, Transcode Therapeutics Inc (RNAZ) has total liabilities worth $3.80 Billion USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Transcode Therapeutics Inc cash flow conversion to assess how effectively this company generates cash.
Transcode Therapeutics Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how Transcode Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check RNAZ asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Transcode Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Transcode Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Advanced Biomed Inc. Common Stock
NASDAQ:ADVB
|
USA | $1.37 Million |
|
Wah Fu Education Group Ltd
NASDAQ:WAFU
|
USA | $3.69 Million |
|
Lianhua Supermarket Holdings Co. Ltd
F:LSJ
|
Germany | €17.10 Billion |
|
Lanakam S.A
AT:LANAC
|
Greece | €4.87 Million |
|
EVE Health Group Limited
AU:EVE
|
Australia | AU$307.63K |
|
Swift Tv Ltd
AU:STV
|
Australia | AU$16.14 Million |
|
DTI Group Ltd
AU:DTI
|
Australia | AU$5.64 Million |
|
Platina Resources Limited
F:P4R
|
Germany | €391.93K |
Liability Composition Analysis (2018–2024)
This chart breaks down Transcode Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see RNAZ market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Transcode Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Transcode Therapeutics Inc (2018–2024)
The table below shows the annual total liabilities of Transcode Therapeutics Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.31 Million | +163.91% |
| 2023-12-31 | $3.53 Million | -18.83% |
| 2022-12-31 | $4.35 Million | +71.55% |
| 2021-12-31 | $2.53 Million | -43.23% |
| 2020-12-31 | $4.46 Million | +239.63% |
| 2019-12-31 | $1.31 Million | +82.89% |
| 2018-12-31 | $718.61K | -- |
About Transcode Therapeutics Inc
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its… Read more